Latest News-I-Mab-天境生物科技(上海)有限公司 Mediaroom

I-Mab Announces Upcoming Participation at January Conferences

SHANGHAI and GAITHERSBURG, Md., Dec. 23, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2020-12-23 21:00 4999

I-Mab Added to Nasdaq Biotechnology Index

SHANGHAI and GAITHERSBURG, Md., Dec. 14, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2020-12-14 21:00 7498

I-Mab Accelerates Clinical Development of Anti-CD47 Monoclonal Antibody Lemzoparlimab in the US and China

SHANGHAI and GAITHERSBURG, Md., Dec. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2020-12-04 21:00 7372

I-Mab Files Shelf Registration Statement for PIPE Investors

SHANGHAI and GAITHERSBURG, Md., Dec. 1, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2020-12-02 05:23 8883

I-Mab Appoints Leading Immunology and Hematology Experts to Its Scientific Advisory Board

SHANGHAI and GAITHERSBURG, Md., Dec. 1, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2020-12-01 21:00 2348

I-Mab Appoints Leading Immunology and Hematology Experts to Its Scientific Advisory Board

I-Mab Announces Preclinical Data on Differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020

SHANGHAI and GAITHERSBURG, Md., Nov. 11, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2020-11-11 21:00 4401

I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting

SHANGHAI and GAITHERSBURG, Md., Nov. 9, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2020-11-09 21:12 2939

I-Mab Announces Upcoming Participation at November Conferences

SHANGHAI, China, and GAITHERSBURG, MD., Oct. 28, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq...

2020-10-28 20:00 2076

I-Mab to Present Preclinical Data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

SHANGHAI and GAITHERSBURG, Md., Oct. 27, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2020-10-27 20:05 3700

I-Mab Receives China CDE Approval to Initiate Phase 3 Clinical Trial of Eftansomatropin in Pediatric Patients with Growth Hormone Deficiency

SHANGHAI and GAITHERSBURG, Md., Sept. 30, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB)...

2020-09-30 20:00 10942

I-Mab Announces China NMPA Clearance for Phase 1 Clinical Trial of Lemzoparlimab in Relapsed or Refractory Advanced Lymphoma

SHANGHAI and GAITHERSBURG, Md., Sept. 21, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB)...

2020-09-21 20:00 5288

MorphoSys and I-Mab Announce FDA Clearance of IND Application for MOR210/TJ210 in Patients with Advanced Cancer

PLANEGG/MUNICH, Germany and SHANGHAI, China, Sept. 17, 2020 /PRNewswire/ -- MorphoSys AG (FSE: MOR;...

2020-09-18 04:05 10029

I-Mab Announces Upcoming Participation at September Conferences

SHANGHAI and GAITHERSBURG, Md., Sept. 8, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2020-09-08 20:00 8667

I-Mab Announces $418 Million Private Placement with Hillhouse Capital-Led Consortium

SHANGHAI and GAITHERSBURG, Md., Sept. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2020-09-04 19:01 10186

AbbVie and I-Mab Enter into Global Strategic Partnership for Differentiated Immuno-oncology Therapy

NORTH CHICAGO, Illinois and SHANGHAI, China, Sept. 4, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) and ...

2020-09-04 19:00 9630

I-Mab Reports Financial Results for the Six Months Ended June 30 and Provides Corporate Update

Positive preliminary clinical trial results for lemzoparlimab (TJC4) demonstrate a differentiated d...

2020-08-31 19:00 13054

I-Mab Announces First Patient Dosed in Phase 1b Study of Plonmarlimab in Rheumatoid Arthritis in China

SHANGHAI and GAITHERSBERG, Md., Aug. 17, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2020-08-17 20:00 2733

I-Mab to Report Financial Results for the Six Months Ended June 30, 2020 and Provide Corporate Update on August 31, 2020

SHANGHAI and GAITHERSBURG, Md., Aug. 6, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2020-08-06 20:30 13849

China NMPA Accepts IND Application for Eftansomatropin Pivotal Trial in Pediatric Patients with Growth Hormone Deficiency

SHANGHAI and GAITHERSBERG, Md., Aug. 4, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), ...

2020-08-04 20:17 14729

I-Mab Drives Commercialization Strategy with Appointment of Ivan Yifei Zhu as Chief Commercial Officer

SHANGHAI and GAITHERSBERG, Md., July 28, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB),...

2020-07-28 20:22 9486